RT Journal Article
T1 Epidemiology clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain
A1 Escobar, Carlos
A1 Aranda, Unai
A1 Palacios, Beatriz
A1 Capel, Margarita
A1 Sicras, Antoni
A1 Sicras, Aram
A1 Hormigo, Antonio
A1 Alcazar, Roberto
A1 Manito, Nicolas
A1 Botana, Manuel
K1 DAPA-CKD
K1 Death
K1 Chronic kidney disease
K1 Hospitalization
K1 Medication
K1 Outcome
K1 Esc guidelines
K1 Inhibition
K1 Prevalence
AB Objectives: To describe the epidemiology, clinical profile, treatments, and to determine cardiovascular and renal outcomes after two years of follow-up in a contemporary chronic kidneay disease (CKD) population in Spain. This was also analyzed among the DAPA-CKD-like population (patients who met most inclusion criteria of DAPA-CKD trial).Methods: Observational, retrospective, population-based study using BIG-PAC database. The CKD population was defined as patients >= 18 years, with at least one diagnostic code of CKD prior to the index date (January 1st, 2018). CKD was defined as estimated glomerular filtration rate (eGFR) = 18 years, with at least one diagnostic code of CKD prior to the index date (January 1st, 2018). CKD was defined as estimated glomerular filtration rate (eGFR) 30 mg/g.Results: We identified 56,435 CKD patients after exclusions (76.4 years, 52.2% men, urine-album into-creatinine ratio 390.8 mg/g, eGFR 49.7 mL/min/1.73 m(2)). CKD prevalence was4.91% and incidence 2.10 per 1000 patient-years. Regarding treatments, 69.2% were taking renin-angiotensin system inhibitors (only 4.2% at maximal doses) and 3.5% of diabeticpatients SGLT-2 inhibitors. During the two years of follow-up, rates of heart failure, all-cause death, myocardial infarction, stroke, and CKD were 17.9, 12.1, 7.2, 6.3, and 5.9 events per 100 patient-years, respectively. During this period, 44% of patients were hospitalized, and 6.8% died during hospitalization. Cardiovascular outcomes were more common in the DAPACKD-like population.Conclusions: In Spain, CKD population is older and comorbidities, including diabetes and heart failure, are common. Cardiovascular and renal outcomes are frequent. There is room for improvement in CKD management, particularly through the use of drugs with proven cardiovascular and renal benefit. (C) 2021 Sociedad Espanola de Nefrolog ' ia. Published by Elsevier Espana, S.L.U.
PB Soc espanola nefrologia dr rafael matesanz
SN 0211-6995
YR 2021
FD 2021-11-01
LK https://hdl.handle.net/10668/24776
UL https://hdl.handle.net/10668/24776
LA en
DS RISalud
RD Apr 8, 2025